Get 50% OFF This Summer!

Advertisement
AdvertisementAdvertisement
logo

Jagsonpal Pharmaceuticals

JAGSNPHARM
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Jagsonpal Pharmaceuticals Share price and Fundamental Analysis

View All Details
View All Details
Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.
Company Incorporation1978
ChairmanHarsha Raghavan
Head QuartersGurgaon
Previous NameNA

Key Metrics

Market Cap (Cr)
1,391.89
PE Ratio
35.03
Industry P/E
34.61
PEG Ratio
0.1
ROE
16.57%
ROCE
20.43%
ROA
19.9%
Total Debt (Cr)
9.24
Debt to Equity
0.04
Dividend Yield
1.19%
EPS
5.98
Book Value & P/B
36.12 x 5.8
Face Value
2
Outstanding Shares(Cr)
6.64
Current Ratio
6.63
EV to Sales
4.74

Included In

+More

Stock Returns

1 Week-4.46%
1 Month-6.49%
6 Months-21.93%
1 Year+53.1%
3 Years+79.85%
5 Years+2060.1%

CAGR

1 Year CAGR

Revenue Growth

-11.83%

Net Profit Growth

-15.94%

Operating Profit Growth

-11.2%

Dividend Growth

0%

Stock Returns CAGR

+56.71%
no_data

No Stocks

Smart Score

2.3
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 67.78%

FIIs : 2.10%

DIIs : 0.00%

Public : 30.11%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
Promoter Shareholding Decreased by 0.03% to 67.78% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Jagsonpal Pharmaceuticals Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Jagsonpal Pharmaceuticals Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.

The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.

The Company's R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future.

It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia.

In the fiscal 2001, the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

The new manufacturing facility at Pantnagar, Uttarakhand started production in April 2009. The Company launched two brands, Divatrone and ProRetro in the product market segment, Dydrogesterone, which was earlier dominated by a global pharma Company in August, 2021.

Jagsonpal Pharmaceuticals Share Price

Jagsonpal Pharmaceuticals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Jagsonpal Pharmaceuticals Market Cap

Market capitalization of Jagsonpal Pharmaceuticals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Jagsonpal Pharmaceuticals is valued compared to its competitors.

Jagsonpal Pharmaceuticals PE Ratio

Jagsonpal Pharmaceuticals PE ratio helps investors understand what is the market value of each stock compared to Jagsonpal Pharmaceuticals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Jagsonpal Pharmaceuticals PEG Ratio

The PEG ratio of Jagsonpal Pharmaceuticals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Jagsonpal Pharmaceuticals ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Jagsonpal Pharmaceuticals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Jagsonpal Pharmaceuticals ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Jagsonpal Pharmaceuticals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Jagsonpal Pharmaceuticals Total Debt

Total debt of Jagsonpal Pharmaceuticals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Jagsonpal Pharmaceuticals Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Jagsonpal Pharmaceuticals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Jagsonpal Pharmaceuticals CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Jagsonpal Pharmaceuticals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Jagsonpal Pharmaceuticals Technical Analysis

Technical analysis of Jagsonpal Pharmaceuticals helps investors get an insight into when they can enter or exit the stock. Key components of Jagsonpal Pharmaceuticals Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Jagsonpal Pharmaceuticals shares often struggle to rise above due to selling pressure.

Jagsonpal Pharmaceuticals Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Jagsonpal Pharmaceuticals ’s financial health and profitability.

Jagsonpal Pharmaceuticals Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Jagsonpal Pharmaceuticals Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Jagsonpal Pharmaceuticals Financials

The financials of Jagsonpal Pharmaceuticals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Jagsonpal Pharmaceuticals Profit and Loss Statements

The profit and loss statement of Jagsonpal Pharmaceuticals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Jagsonpal Pharmaceuticals .

Jagsonpal Pharmaceuticals Balance Sheet

The balance sheet presents a snapshot of Jagsonpal Pharmaceuticals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Jagsonpal Pharmaceuticals Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.

Download the App

Download the App